Related Experiment Video
Updated: Aug 18, 2025
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
555
Failure patterns for thymic carcinoma with completed resection and postoperative radiotherapy
Yan Gao1, Xingwen Fan2, Chuanli Hua3
1Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Anqing Municipal Hospital, Anhui Province, China.
Summary
Distant failure was most common in thymic carcinoma patients after surgery and radiotherapy. Advanced Masaoka stage and lack of adjuvant chemotherapy independently predicted worse disease-free survival (DFS).
Area of Science:
- Oncology
- Radiation Oncology
- Thoracic Surgery
Background:
- Thymic carcinoma is a rare malignancy.
- Complete resection followed by postoperative radiotherapy (PORT) is a standard treatment approach.
- Understanding disease failure patterns is crucial for optimizing treatment strategies.
Purpose of the Study:
- To evaluate the patterns of disease failure after complete resection and PORT in thymic carcinoma patients.
- To identify risk factors associated with disease failure.
- To assess the effectiveness of current treatment protocols.
Main Methods:
- Retrospective analysis of 127 thymic carcinoma patients treated with PORT after complete resection (2003-2020).
- Data collection included clinical characteristics and radiation fields.
- Failure patterns categorized as locoregional, pleural, or distant.
Main Results:
- Disease failure occurred in 40.2% of patients during a median 64-month follow-up.
- The most frequent failure pattern was distant (32.3%), followed by pleural (22.0%) and locoregional (15.0%).
- Masaoka stage and adjuvant chemotherapy were independent predictors of disease-free survival (DFS).
Conclusions:
- Distant failure is the predominant pattern in thymic carcinoma post-PORT.
- Masaoka stage and adjuvant chemotherapy significantly impact DFS.
- Current tumor bed irradiation appears sufficient for locoregional control in this patient cohort.
